Accelerated Intermittent Theta Burst Stimulation for Depressive Symptoms
Launched by STANFORD UNIVERSITY · Jul 17, 2018
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
This study intends to investigate whether modifying stimulation parameters enables typical 6-8 week long rTMS protocols to be compressed to only five days. The influence of this accelerated protocol on the length of patient stay in the hospital will be investigated.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Over 18 years old
- • Able to read, understand, and provide written, dated informed consent prior to screening. Participants will be deemed likely to comply with study protocol and communicate with study personnel about adverse events and other clinically important information.
- • Currently diagnosed with Major Depressive Disorder (MDD) and/or in a current major depressive episode, according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
- • Currently an inpatient at Stanford Hospital
- • Meet the threshold on the total HAMD17 score of \>/=20 at screening/baseline.
- • Qualifies and has access to outpatient rTMS treatment
- Exclusion Criteria:
- • Any structural lesion e.g. structural neurological condition, more subcortical lesions than would be expected for age, stroke effecting stimulated area or connected areas or any other clinically significant abnormality that might affect safety, study participation, or confound interpretation of study results.
- • Metal implant in brain (e.g. deep brain stimulation), cardiac pacemaker, or cochlear
- • History of epilepsy/ seizures (including history of withdrawal/ provoked seizures)
- • Shrapnel or any ferromagnetic item in the head
- • Pregnancy
- • Autism Spectrum disorder
- • Active substance use (\<1 week) or intoxication verified by toxicology screen--of cocaine, amphetamines, benzodiazepines
- • Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation
- • Cognitive impairment (including dementia)
- • Current severe insomnia (must sleep a minimum of 4 hours the night before stimulation)
- • Current mania
- • Current unmanageable psychosis
- • IQ \<70
- • Showing symptoms of withdrawal from alcohol or benzodiazepines
- • Parkinsonism or other movement d/o determined by PI to interfere with treatment
- • More subcortical lesions than would be expected for age or a stroke effecting stimulated area or connected areas.
- • Any other indication the PI feels would comprise data.
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Palo Alto, California, United States
Patients applied
Trial Officials
Nolan Williams, MD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials